Why the study?
Most existing animal models of Duchenne muscular dystrophy fail to recapitulate the complete skeletal and cardiac disease manifestations observed in affected patients.
Key points are not available for this paper at this time.
Population
Dmd Δ52-54 mouse model
Design
Preclinical animal model development and characterization study
Answers are grounded in this paper and cite their sources.
New DMD mouse model with early cardiomyopathy extends preclinical testing options; leaves open clinical translation pending further validation.
Duchenne muscular dystrophy (DMD) is a life-threatening neuromuscular disease caused by the lack of dystrophin, resulting in progressive muscle wasting and locomotor dysfunctions. By adulthood, almost all patients also develop cardiomyopathy, which is the primary cause of death in DMD. Although there has been extensive effort in creating animal models to study treatment strategies for DMD, most fail to recapitulate the complete skeletal and cardiac disease manifestations that are presented in affected patients. Here, we generated a mouse model mirroring a patient deletion mutation of exons 52-54 (Dmd Δ52-54). The Dmd Δ52-54 mutation led to the absence of dystrophin, resulting in progressive muscle deterioration with weakened muscle strength. Moreover, Dmd Δ52-54 mice present with early-onset hypertrophic cardiomyopathy, which is absent in current pre-clinical dystrophin-deficient mouse models. Therefore, Dmd Δ52-54 presents itself as an excellent pre-clinical model to evaluate the impact on skeletal and cardiac muscles for both mutation-dependent and -independent approaches.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: